Sareum Holdings Plc (LON:SAR) has successfully demonstrated the potential of one of its drug candidates to tackle a rare and difficult-to-treat form of leukaemia.
The TYK2 inhibitor was assessed as part of a feasibility study to see whether it might work in t-cell acute lymphoblastic leukaemia (T-ALL), which occurs in late childhood and early adolescence.
''What we're trying to develop here is a targeted therapy rather than using effectively poisons, which are what chemotherapy is - this is more of a rational approach where we're looking to tackle the Achilles heel of the cancer'', Dr Reader added.
The early-stage work was supported by Innovate UK and a grant of £140,000.